India, Sept. 7 -- image credit- freepik

Hyderabad-based HRV Pharma, a global asset-light pharmaceutical platform, has announced strategic investments to expand its capabilities across two high-value and supply-constrained pharmaceutical segments, synthetic peptides and high-potency oncology APIs.

These initiatives are designed to strengthen HRV's portfolio of complex molecules, accelerate access to regulated markets, and create dedicated supply capabilities while continuing to operate through its asset-light business model.

HRV Pharma is investing as part of a combined Rs 40 to Rs 50 crore programme to establish dedicated cGMP peptide manufacturing capacity through a strategic capacity underwriting arrangement. The initiative will focu...